8.29
0.79%
+0.07
Precedente Chiudi:
$8.22
Aprire:
$8.25
Volume 24 ore:
1.01M
Capitalizzazione di mercato:
$1.32B
Reddito:
$442.74M
Utile/perdita netta:
$-1.00B
Rapporto P/E:
-1.3725
EPS:
-6.04
Flusso di cassa netto:
$183.15M
1 W Prestazione:
+2.54%
1M Prestazione:
+0.79%
6M Prestazione:
-7.84%
1 anno Prestazione:
-20.57%
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Nome
Ironwood Pharmaceuticals Inc
Settore
Telefono
617-621-7722
Indirizzo
301 Binney Street, Cambridge, MA
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-01-17 | Iniziato | Craig Hallum | Buy |
2023-12-14 | Iniziato | Wells Fargo | Overweight |
2023-11-09 | Iniziato | Jefferies | Buy |
2023-09-28 | Iniziato | JMP Securities | Mkt Outperform |
2022-09-02 | Iniziato | CapitalOne | Overweight |
2022-04-22 | Iniziato | Piper Sandler | Overweight |
2020-09-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2020-06-17 | Iniziato | Northland Capital | Outperform |
2019-07-10 | Ripresa | Credit Suisse | Neutral |
2019-03-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
2019-02-25 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
2019-01-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
2018-11-07 | Downgrade | Credit Suisse | Outperform → Neutral |
2018-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
2018-07-23 | Iniziato | H.C. Wainwright | Sell |
2018-05-09 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2018-01-05 | Downgrade | BofA/Merrill | Buy → Underperform |
2017-12-06 | Downgrade | Mizuho | Buy → Neutral |
2017-07-21 | Downgrade | JP Morgan | Overweight → Neutral |
2017-05-03 | Iniziato | Wells Fargo | Outperform |
2017-04-07 | Reiterato | Mizuho | Buy |
2017-02-22 | Reiterato | Barclays | Equal Weight |
2016-11-04 | Reiterato | Mizuho | Buy |
2016-10-24 | Reiterato | Wedbush | Neutral |
2016-10-10 | Reiterato | Mizuho | Buy |
2016-09-27 | Reiterato | WallachBeth | Hold |
Mostra tutto
Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to Decline
Zacks Investment Research
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
Zacks Investment Research
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March
Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Nasdaq Gains 100 Points Following PCE Data
Benzinga
Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge
Benzinga
Ironwood Pharmaceuticals Inc Azioni (IRWD) Dati Finanziari
Ironwood Pharmaceuticals Inc (IRWD) Reddito 2024
IRWD ha riportato un ricavo (TTM) di $442.74 milioni per il trimestre terminato il 2023-12-31, un +7.83% salita anno su anno.
Ironwood Pharmaceuticals Inc (IRWD) Reddito netto 2024
IRWD l'utile netto (TTM) è stato di -$1.00 miliardi per il trimestre terminato il 2023-12-31, un -672.50% diminuire anno su anno.
Ironwood Pharmaceuticals Inc (IRWD) Flusso di cassa 2024
IRWD ha registrato un flusso di cassa disponibile (TTM) di $183.15 milioni per il trimestre conclusosi con 2023-12-31, un -33.06% diminuire anno su anno.
Ironwood Pharmaceuticals Inc (IRWD) Utile per azione 2024
L'utile per azione (TTM) di IRWD è stato pari a -$6.51 per il trimestre terminato il 2023-12-31, un -771.13% declino anno su anno.
Ironwood Pharmaceuticals Inc Azioni (IRWD) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
John Minardo | Chief Legal Officer |
Mar 08 '24 |
Option Exercise |
0.00 |
32,752 |
0 |
311,975 |
MCCOURT Thomas A | Chief Executive Officer |
Mar 08 '24 |
Option Exercise |
0.00 |
120,298 |
0 |
1,217,948 |
Davis Andrew | SVP, Chief Business Officer |
Mar 08 '24 |
Option Exercise |
0.00 |
37,120 |
0 |
310,756 |
Emany Sravan Kumar | SVP, Chief Financial Officer |
Mar 08 '24 |
Option Exercise |
0.00 |
37,120 |
0 |
338,853 |
Duane Jon R | Director |
Mar 06 '24 |
Buy |
8.70 |
6,920 |
60,204 |
121,028 |
Emany Sravan Kumar | SVP, Chief Financial Officer |
Mar 04 '24 |
Buy |
9.38 |
10,684 |
100,216 |
301,733 |
MCCOURT Thomas A | Chief Executive Officer |
Feb 12 '24 |
Sale |
15.24 |
177,164 |
2,699,979 |
832,774 |
John Minardo | Chief Legal Officer |
Feb 12 '24 |
Sale |
15.24 |
47,380 |
722,071 |
224,796 |
Shetzline Michael | CMO,SVP,Head-Res&Drug |
Feb 12 '24 |
Sale |
15.24 |
38,618 |
588,538 |
340,484 |
Davis Andrew | SVP, Chief Business Officer |
Feb 12 '24 |
Sale |
15.24 |
9,846 |
150,053 |
208,324 |
Capitalizzazione:
|
Volume (24 ore):